Data from an interim analysis of the international Phase III trial ENDEAVOUR, a head-to-head comparison of Kyprolis (carfilzomib) and low-dose dexamethasone versus Velcade and low-dose dexamethasone for relapsed myeloma patients, have recently been released by the pharmaceutical company, Amgen. They showed that patients treated with Kyprolis and dexamethasone had twice the progression free survival of patients treated with Velcade and dexamethasone. Further results from the trial are expected to be presented at the American Society for Clinical Oncology Meeting in June.


Read full article